Surgery for Intravenous Leiomyomatosis (SIVL)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Li Yang, General Hospital of Beijing PLA Military Region
ClinicalTrials.gov Identifier:
NCT01707862
First received: October 14, 2012
Last updated: October 15, 2012
Last verified: October 2012

October 14, 2012
October 15, 2012
March 1997
April 2012   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01707862 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Surgery for Intravenous Leiomyomatosis
Surgical Management of Intravenous Leiomyomatosis With Intracardiac Extension: Our Experience and Outcomes

Intravenous leiomyomatosis (IVL) with intracardiac extension is a rare benign smooth muscle tumor. Reviewing literature, intracardiac extension of the IVL has been reported in at least 70 cases. Most are individual case reports. Surgical experience is not much. However, different opinion of surgical strategies remain controversial. The purpose of this report is to describe our experience of surgical management for the IVL with intracardiac extension.

All patients underwent surgical management. Clinical data were obtained from medical reports. Following-up was made through email and telephone.

Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

From March 1997 to June 2011, 6 women patients were admitted to our hospital with intravenous leiomyomatosis with intracardiac extension.

Leiomyomatosis
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
6
October 2012
April 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age more than 18 years.
  • Tumor markers were all within normal limits.
  • Patients underwent surgical management.
  • Patients were followed-up for more than 12 months.

Exclusion Criteria:

-Tumor markers were all within abnormal limits

Female
18 Years to 80 Years
Yes
Contact information is only displayed when the study is recruiting subjects
China
 
NCT01707862
GHBeijing-20121012
Yes
Li Yang, General Hospital of Beijing PLA Military Region
Li Yang
Not Provided
Principal Investigator: Genetal Hospital Beijing Military Region, First class Institute of Cardiovascular Disease
General Hospital of Beijing PLA Military Region
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP